Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-05-19
1996-04-02
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514474, 549315, 549316, A61K 31365, C07D30762
Patent
active
055041078
ABSTRACT:
The present invention relates to a method for synthesis of optically pure 4-alkenyl or 4-alkanyl-2-hydroxytetronic acids from an optically pure aldehyde. The invention further relates to the use of such optically pure compounds as potent inhibitors of platelet aggregation by working at the level of cyclooxygenase. The invention further relates to the pharmaceutical use of such compounds in the treatment of coronary artery diseases, especially in the treatment and/or prevention of atherosclerosis.
REFERENCES:
patent: 5008405 (1991-04-01), Hatanaka et al.
patent: 5298526 (1994-03-01), Witiak et al.
Haynes et al., "Tetronic Acids" Chem. Soc.: Quart. Rev., 1960, 292-315.
Ireland and Thompson, "An approach to the total synthesis of chlorothrieolide: the synthesis of the top half" J. Org. Chem., 1979, 44:3041-3052.
Kamanna et al., "Serum Lipoprotein and apoprotein concentrations in 4-(4-chlorophenyl)-2-hydroxytetronic acid and clofibrate-treated cholesterol and cholic acid-fed rats" Lipids, 1989, 24:25-32.
Schank, "Reductones," Synthesis, 1972, 176-190.
Triozzi et al., "Aci-reductones enhance interleukin-2-induced lymphocytic cytotoxicity", Int. J. Immunopharmac., 1993, 15:47-54.
Witiak et al., "4-substituted-2-hydroxytetronic acid aci-reducones improve lymphokine-activated killer cell activity in vitro" Proc. Am. Assoc. Canc. Res., 1993, Florida (#2665).
Witiak et al., "Chemical Approaches to the treatment of artherosclerosis" in Trends in Medicinal Chemistry, Blackwell Scientific Publications: Oxford, 1990, pp. 243-256.
Witiak et al., "Efficient synthesis for optically pure stereogenically labile 4-substituted-2-hydroxytetronic acids" J. Org. Chem., 1990, 55:1112-1114.
Witiak et al., "Medicinal chemistry aspects of antilipidemic drugs: aci-reductone antilipidemic and antiaggregatory agents" Actual Chem. Ther., 1988, 15:41-62.
Witiak et al., "Synthetic aci-reductones: 3,4-dihdyroxy-2H-1-benzopyran-2-ones and their trans-4a,5,6,7,8,8a-hexahydro diastereomers" J. Med. Chem., 1988, 31:1437-1445.
Witiak and Tehim, "Synthetic approaches to 4-spiro-2-hydroxytetronic acids" J. Org. Chem., 1987, 52:2324-2327.
Witiak et al., "Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox and analogues and their relationship to clofibric acid" J. Med. Chem., 1986, 29:2170-2174.
Witiak et al., "Comparative antiaggregatory activity in human platelets of a benzopyranone aci-reductone, clofibric acid, and a 2,3 dihydrobenzofuran analogue" J. Med. Chem., 1982, 25:90-93.
Mantri Padmaja
Witiak Donald T.
Raymond Richard L.
The Ohio State University Research Foundation
LandOfFree
Optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytetronic acids a does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytetronic acids a, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytetronic acids a will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2016581